Proteus Digital Health

Back to Press Releases
5 July, 2012

Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products

REDWOOD CITY, CA, and TOKYO, JAPAN, July 5, 2012 – Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. announced they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new category of medicines. These new medicines will be based on Otsuka’s pharmaceutical products and Proteus’s digital health feedback system incorporating Proteus’s novel sensor-based technologies. Under the agreement, Proteus and Otsuka have entered an exclusive collaboration to develop commercial products in two defined therapeutic areas of high unmet medical need. Otsuka has also been granted a non-exclusive license to utilize Proteus technology in its clinical research and development activities.

Financial terms of the agreement were not disclosed.

The Proteus digital health feedback system combines wearable and ingestible sensor technologies that together are designed to help improve patients’ health habits. Detailed information, including when a medication has been taken as well as activity and rest patterns, is captured and delivered to a secure database. The information, accessible from a variety of platforms such as mobile phones with consent granted by the patient, is designed to help patients and their caregivers better manage their conditions and to help clinicians provide more effective care.

About Proteus Digital Health

Proteus Digital Health, formally known as Proteus Biomedical, Inc, believes in better health, powered by you. Proteus’s wearable and ingestible sensor technology is used to deliver digital medications and other health and wellness products. Headquartered in Redwood City, CA, Proteus partners with and licenses to leading companies to commercialize digital health products, including Otsuka, Novartis, Avery Dennison, Medtronic,ON Semiconductor, Kaiser Permanente and Lloydspharmacy. For more information, please visit

About Otsuka Pharmaceutical Co., Ltd.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.’ Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment.

Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The Otsuka Group has business operations in 24 countries and regions around the world, with consolidated sales of ¥1,154.6 billion for fiscal year 2011. For more information, visit

Press Office

For product images, video footage and interview requests, please contact the Proteus Press Office. Media requests only.

Contact Us

For general inquiries regarding Proteus or our products:

Proteus Digital Health, Inc.
2600 Bridge Parkway
Redwood City, CA 94065
3956 Point Eden Way
Hayward, CA 94545